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Summary
Natural products are traditionally the main source of
drug leads. In particular, many antitumour compounds
are either natural products or derived from them.
However, the search for novel antitumour drugs active
against untreatable tumours, with fewer side-effects or
with enhanced therapeutic efficiency, is a priority goal
in cancer chemotherapy. Microorganisms, particularly
actinomycetes, are prolific producers of bioactive
compounds, including antitumour drugs, produced as
secondary metabolites. Structural genes involved in
the biosynthesis of such compounds are normally
clustered together with resistance and regulatory
genes, which facilitates the isolation of the gene
cluster. The characterization of these clusters has
represented, during the last 25 years, a great source of
genes for the generation of novel derivatives by using
combinatorial biosynthesis approaches: gene inacti-
vation, gene expression, heterologous expression of
the clusters or mutasynthesis. In addition, these tech-
niques have been also applied to improve the pro-
duction yields of natural and novel antitumour
compounds. In this review we focus on some repre-
sentative antitumour compounds produced by actino-
mycetes covering the genetic approaches used to
isolate and validate their biosynthesis gene clusters,
which finally led to generating novel derivatives and to
improving the production yields.
Introduction
The production of bioactive compounds (antibiotic, anti-
fungal, antitumour, immunosuppressant, antiviral or
antiparasitic agents) from living organisms is mainly
supported by microorganisms. From them the most pro-
lific producers are fungi, cyanobacteria, myxobacteria and
actinobacteria, mainly actinomycetes. About half of all
bioactive microbial metabolites discovered to date are
produced by actinomycetes, with the genus Streptomyces
as the primary bioactive metabolite-producing organism
exploited by the pharmaceutical industry (Bérdy, 2005;
Newman and Cragg, 2007; Butler, 2008; Olano et al.,
2009a). This has stimulated for half a century the study
of actinomycetes at all levels: taxonomy, genetics and
physiology.
Actinomycetes have large genomes (five to nine mega-
bases) and use 5–10% of their DNA for the production of
secondary metabolites (Baltz, 2008); a good number of
them are antitumour drugs (Figs 1 and 2). These belong
to different structural groups: polyketides such as anthra-
cyclines daunomycin and doxorubicin, both promoting
DNA cleavage mediated by DNA topoisomerase II, or
aureolic acids mithramycin and chromomycin A3 that
cause DNA-dependent inhibition of RNA synthesis and
inhibit topoisomerase I causing DNA cleavage; non-
ribosomal peptides such as glycopeptide actinomycin D,
which inhibits DNA-directed RNA synthesis by binding to
double stranded DNA; mixed polyketide/non-ribosomal
peptides as glycopeptide bleomycin, which inhibits DNA
synthesis through a metal-dependent oxidative cleavage
of DNA; heterocyclic quinones as mitomycin C that cause
intra- and inter-strand DNA cross-linking leading to selec-
tive inhibition of DNA synthesis; indolocarbazoles such as
protein kinases inhibitor staurosporine and topoi-
somerase I-dependent DNA-damaging agent rebeccamy-
cin, etc. However, even considering the enormous
number of natural products discovered to date, there is
still a need for generating novel drugs to be used in
cancer chemotherapy due to the rapid development of
resistance to multiple chemotherapeutic drugs and the
high toxicity usually associated with this type of drugs and
their undesirable side-effects. In addition, there is a
demand for novel antitumour drugs active against untreat-
able tumours, with fewer side-effects or with greater thera-
peutic efficiency. To this respect, enormous efforts are
under way to discover new drugs from actinomycetes by
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searching uncommon actinomycetes in special ecological
niches, mining genomes for cryptic pathways, and apply-
ing combinatorial biosynthesis to generate novel second-
ary metabolites related to existing pharmacophores
(Baltz, 2008).
The utilization of combinatorial biosynthesis has
become an important alternative approach for developing
novel derivatives and for improving production yields of
known antitumour compounds (Olano et al., 2008a; 2010).
The strategies used in combinatorial biosynthesis (Fig. 3)
involve gene inactivation to generate mutant strains that
might accumulate novel products, expression of genes or
combination of genes in different heterologous hosts
including mutant strains or producers of related com-
pounds, and mutasynthesis (Méndez and Salas, 2003;
Floss, 2006; Menzella and Reeves, 2007; Kennedy, 2008;
Salas and Méndez, 2009). Obviously, the application of this
technology requires the isolation and characterization of
the gene cluster involved in the biosynthesis of a particular
antitumour compound to unravel its biosynthetic pathway.
A large number of antitumour biosynthesis gene
clusters have been characterized from producing
Fig. 1. Structures of some polyketide and non-ribosomal peptide antitumour compounds produced by actinomycetes.
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Fig. 2. Structures of some mixed polyketide/non-ribosomal peptide, indolocarbazole and heterocyclic quinone antitumour compounds
produced by actinomycetes.
Fig. 3. Strategies used for generating novel antitumour derivatives and improving production yields by combinatorial biosynthesis.
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actinomycetes during the last 25 years (Olano et al.,
2009b). In this review, we focus on the approaches used
for the isolation and validation of secondary metabolite
biosynthesis gene clusters from antitumour-producing
actinomycetes (Table 1). We will summarize the genetic
information that can be gathered from those clusters. We
will also address the subsequent use of this information
for the development of novel derivatives through combi-
natorial biosynthesis as well as for the improvement of
production titres.
Isolation and characterization of gene clusters
Strategies used for the isolation of the gene clusters
covered by this review do not differ from those used for
the identification of clusters involved in the biosynthesis of
non-antitumour secondary metabolites. Furthermore, in
most cases more than one strategy has been applied for
the isolation of a single cluster. One of these approaches
is based in the fact that structural biosynthetic genes are
generally clustered all together with resistance and regu-
latory genes. This has facilitated the identification of
several biosynthetic clusters by cloning resistance genes
in an appropriate sensitive host as in the case of these
involved in the biosynthesis of bleomycin (Sugiyama
et al., 1994a) or mitomycin C (August et al., 1994). In
addition, it has been observed that genes from biosyn-
thetically related pathways show cross-hybridization each
other. This has prompted the homology-based approach
as the most widely method applied for the identification of
biosynthesis gene clusters (Table 1). Heterologous DNA
probes were used for the isolation of several clusters as
for those involved in the biosynthesis of daunorubicin/
doxorubicin (Otten et al., 1990), anthracycline-like ellora-
mycin (Decker et al., 1995), serine-threonine kinase
mTOR inhibitor rapamycin (Schwecke et al., 1995), mith-
ramycin (Lombó et al., 1996), angucycline oviedomycin
(Méndez et al., 2002), chromomycin A3 (Menéndez et al.,
2004a) and angiogenesis inhibitor borrelidin (Olano et al.,
2004a). Homologous probes, previously identified or gen-
erated by using degenerated oligonucleotides, have also
been used for the isolation of actinomycin D (Schau-
wecker et al., 1998), the DNA-cleaving agent enediyne
C-1027 (Liu and Shen, 2000), rebeccamycin (Sánchez
et al., 2002), staurosporine (Onaka et al., 2002), the
chaperone Hsp90 inhibitor geldanamycin (Rascher et al.,
2003) and the DNA polymerase a inhibitor depsipeptide
thiocoraline (Lombó et al., 2006) biosynthesis gene clus-
ters. On the other hand, the method for isolating anthra-
cycline steffimycin gene cluster was the direct inactivation
of a gene involved in its biosynthesis using a PCR frag-
ment that was amplified from steffimycin producer chro-
mosomal DNA and used to generate a non-producing
mutant (Gullón et al., 2006). Finally, genome sequencing
and mining is now a consolidated tool to identify novel
biosynthesis gene clusters. Sequencing of Salinispora
tropica CNB-440 genome was used to locate the 20S
proteasome inhibitor salinosporamide A gene cluster
(Udwary et al., 2007).
Once a gene cluster has been isolated, it is necessary
to confirm its involvement in the biosynthesis of the bio-
active compound. The validation process is especially
important for clusters identified by homology-based
approaches and genome mining and can be achieved by
several methods that include gene inactivation or the het-
erologous expression of the cluster. The main objective of
gene inactivation is the generation of non-producing
mutants as a proof of the involvement of the cluster in the
biosynthesis of the compound under study. The expres-
sion of gene clusters involves the utilization of genetic
tools to mobilize large DNA fragments into a heterologous
host to produce the pursued compound. It takes advan-
tage of the availability of a number of Streptomyces
strains [mainly S. coelicolor A3(2), S. lividans 66, S. ven-
ezuelae YJ003 or S. albus J1074] to be used as hosts due
to the deep knowledge accumulated about their physiol-
ogy and growth conditions. In addition, some of these
strains have been engineered to enhance the expression
of heterologous gene clusters. Streptomyces lividans was
the host used for the expression of elloramycin (Decker
et al., 1995; Ramos et al., 2008), staurosporine (Onaka
et al., 2002), oviedomycin (Méndez et al., 2002) and thio-
coraline (Lombó et al., 2006) gene clusters. Streptomyces
albus was used for the production of oviedomycin
(Méndez et al., 2002), rebeccamycin (Sánchez et al.,
2002), staurosporine (Salas et al., 2005), thiocoraline
(Lombó et al., 2006) and steffimycin (Gullón et al., 2006).
Furthermore, low levels of rebeccamycin production were
also achieved in Escherichia coli (Hyun et al., 2003).
In addition, gene inactivation and heterologous expres-
sion of the cluster are also used to establish the cluster
boundaries.
Structural genes
Most of the genes in a cluster code for enzymes involved
in the biosynthetic process, including the biosynthesis of
precursor units, assembling of precursors, generation of
other structural elements and tailoring modifications by
attachment of the different structural elements or introduc-
tion of chemical functionalities (Fig. 4).
Biosynthesis of precursors. Some secondary metabolites
are built using, as scaffold elements, precursors not sup-
plied by primary metabolism or, when supplied, an extra
amount is required at due time for the production of the
secondary metabolite. These elements serve as starter
units for the initiation of the pathway or as extender units.
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Genes belonging to this group are found mainly in
polyketide and non-ribosomal peptide biosynthetic path-
ways (Fig. 4).
Nine genes are present in the borrelidin cluster for the
biosynthesis of cyclopentane dicarboxylic acid which is
used as starter unit by a type I PKS. This precursor is
proposed to derive from tyrosine catabolism through
5-oxo-pent-3-ene-1,2,5-tricarboxyilic acid (Olano et al.,
2004a). In other cases, such as in the geldanamycin
pathway, only one gene (gdmO) of those required for the
biosynthesis of the type I PKS starter unit 3-amino-5-
hydroxybenzoic acid (AHBA) is present in the cluster
(Rascher et al., 2003). The remaining genes are located
elsewhere in the chromosome as it happens in the
ansamitocin biosynthesis gene cluster (Yu et al., 2002).
However, in the case of mitomycin C, all genes required
for the biosynthesis of AHBA are located in the cluster
(Mao et al., 1999a). The geldanamycin gene cluster con-
tains, in addition, five genes proposed to be involved in
the biosynthesis of PKS extender unit methoxy-malonyl-
CoA (Rascher et al., 2003). In the case of type II PKS
systems, there is no need for a special starter unit since
the biosynthesis of these polyketides usually starts with
an acetyl-CoA unit. However, an extra supply of the
extender malonyl-CoA units is occasionally required. This
might be the case of the oviedomycin pathway since
genes encoding the three subunits of an acetyl-CoA car-
boxylase involved in the production of malonyl-CoA are
present in the cluster (Lombó et al., 2004a; D. Zabala,
pers. comm.).
NRPS systems for the biosynthesis of peptide or mixed
polyketide-peptide compounds occasionally require
Fig. 4. Genetic organization of antitumour biosynthesis gene clusters summarized in Table 1.
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special starter units synthesized by dedicated enzymes
whose genes are present in the cluster. Thiocoraline and
actinomycin D starter units, 3-hydroxy-quinaldic acid and
4-methyl-3-hydroxyanthranilic acid, respectively, derive
from tryptophan. Both are produced through six enzy-
matic steps, the corresponding genes being located in
their respective gene clusters (Lombó et al., 2006; Keller
et al., 2010). Rapamycin PKS uses a shikimate-derived
4,5-dihydroxycyclohex-1-enecarboxylic acid as starter
unit, while its NRPS incorporates L-lysine-derived
L-pipecolic acid. Two genes of this cluster are involved in
the biosynthesis of these precursor units: pteridine-
dependent dioxygenase rapK and L-lysine cyclodeami-
nase rapL (Molnár et al., 1996; Gregory et al., 2005). In
the case of salinosporamide A, there are 13 genes
involved in the biosynthesis of two precursors, substrates
of the NRPS and PKS systems. On one hand, eight genes
are involved in the production of 3-(cyclohex-2-
enyl)alanine derived from prephenate, probably origi-
nated in the shikimic acid pathway. On the other hand,
five genes are required for the production of
chloroethylmalonyl-CoA, derived from S-adenosyl-
methionine (SAM) (Beer and Moore, 2007; Gulder and
Moore, 2009).
Inactivation of genes involved in biosynthesis of starter
units generally leads to non-producing mutants and has
been used for abrogating the production of mitomycin C
(Mao et al., 1999b), borrelidin (Olano et al., 2004a),
geldanamycin (Gregory et al., 2005) or salinosporamide A
(Eustáquio and Moore, 2008). In addition, some of these
mutant strains have been used afterwards for mutasyn-
thesis approaches in the generation of novel derivatives.
Biosynthesis of the structural core. A good number (in
some cases up to 50%) of genes in each cluster are
involved in the assembling of precursor units leading to
the formation of the structural core of compounds. PKS
and NRPS encoding genes are some examples. The
carbon skeleton of polyketides are synthesized by step-
wise decarboxylative Claisen-type condensation of acyl-
CoA precursors that are further reduced and modified.
Type I PKSs are multifunctional enzymes that are orga-
nized into modules, each harbouring a set of distinct
activities (ketosynthase, acyltransferase and acyl-carrier
protein domains) responsible for the catalysis of one cycle
of polyketide chain elongation. These modules can
contain, in addition, further domains to reduce keto
groups (ketoreductase, dehydratase or enoylreductase)
generated during the condensation process, and a
thioesterase domain in the last module for polyketide
release and cyclization (Fischbach and Walsh, 2006).
Most type I PKSs act non-iteratively, thus maintaining the
co-linearity rule of ‘one extension cycle–one PKS
module’. This is the case of PKSs involved in geldanamy-
cin (Rascher et al., 2003) or rapamycin (Schwecke et al.,
1995) biosynthesis. Other type I PKSs are iterative, as
those involved in enediyne C-1027 biosynthesis, where a
single module performs all cycles of polyketide chain
elongation (Liu et al., 2002). There are also type I PKSs
that contain both type of modules: non-iterative and itera-
tive, such as borrelidin PKS (Olano et al., 2003). On the
other hand, type II PKSs are multienzyme complexes
composed by ketosynthase, chain length factor and acyl-
carrier proteins, which carry out a single set of iteratively
acting activities followed by enzymes dedicated to cycliza-
tion and aromatization processes (Shen, 2003). This type
of PKS is involved in the biosynthesis of aromatic
polyketides such as daunorubicin/doxorubicin, tetracy-
cline, mithramycin, chromomycin A3, oviedomycin, steffi-
mycin or elloramycin.
NRPSs synthesize non-ribosomal peptides using as
monomeric building blocks proteinogenic and non-
proteinogenic amino acids, including D-amino acids, and
other carboxylic acids. The NRPS assembly lines follow
the same chemical logic as PKSs for chain elongation
with several domains (in this case adenylation, conden-
sation and peptidyl-carrier protein) organized into
modules. Additional domains with epimerization, methyl-
transferase, reductase or oxidase activity might be also
present. These multimodular enzymes are required for the
biosynthesis of several antitumour compounds such as
thiocoraline (Lombó et al., 2006), actinomycin D (Keller
et al., 2010) and mixed polyketide–peptide compounds
such as rapamycin (Schwecke et al., 1995), bleomycin
(Shen et al., 2002) or salinosporamide A (Udwary et al.,
2007). The presence of type I PKSs and/or NRPSs coding
genes determine the large genetic extension of the bio-
synthesis clusters that harbour these systems. Consider-
ing that a regular PKS or NRPS module is encoded by
approximately 5 kb of DNA, in general the length of the
cluster gets bigger as the number of modules grows
(Table 1 and Fig. 4).
Heterocyclic quinone mitomycin C and indolocarba-
zoles staurosporine and rebeccamycin use other types of
enzymes to assemble their structural cores. Mitomycin
C pathway requires a glycosyltransferase, MitB, and
an acyl-CoA ligase, MitE, to condense AHBA and
D-glucosamine to generate the mitosane core (Mao et al.,
1999a). On the other hand, indolocarbazole cores arcyri-
aflavin (the non-chlorinated aglycone for rebeccamycin)
and K252c (for staurosporine) are synthesized through
the condensation of L-tryptophan moieties after an oxida-
tive deamination and several oxidation and decarboxyla-
tion steps (Sánchez et al., 2002; Salas et al., 2005).
Inactivation of genes involved in the assembling of pre-
cursor units also leads to non-producing mutants. This
has been shown by inactivating C-1027 (Liu et al., 2002),
mithramycin (Lombó et al., 1996), oviedomycin (Lombó
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et al., 2004a) and borrelidin (Olano et al., 2004a) PKS-
encoding genes, thiocoraline (Lombó et al., 2006) NRPS-
encoding genes, and mitomycin C mitB and mitE (Mao
et al., 1999a).
Biosynthesis of deoxysugars and other structural
elements. Attached to the structural core there are
usually other structural elements that, in most cases, cor-
respond to 6-deoxyhexoses derived from D-glucose-1-
phosphate. The sugar moieties contribute to the structural
biodiversity of compounds and participate in the interac-
tion between the drug and the cellular target (Salas and
Méndez, 2007; Méndez et al., 2008). These structures
can be composed by monosaccharides (C-10127,
daunorubicin/doxorubicin, elloramycin, steffimycin and
staurosporine), disaccharides (bleomycin, mithramycin
and chromomycin A3), trisaccharides (mithramycin and
chromomycin A3) and oligosaccharides (landomycin A)
(Figs 1 and 2).
The absence of some or all genes involved in the bio-
synthesis of the sugar from the cluster is the exception
rather than the rule. L-rhamnose-containing clusters con-
stitute such an exception. The gene clusters for steffimy-
cin (Gullón et al., 2006) and elloramycin (Ramos et al.,
2008) do not contain any L-rhamnose biosynthesis genes.
This is a common feature to other clusters containing
L-rhamnose in the structures of the bioactive compounds
and involved in the biosynthesis of polyketides as
spinosad (Waldron et al., 2001) and aranciamycin
(Luzhetskyy et al., 2007) or the diterpenoid brasilicardin A
(Hayashi et al., 2008). In two cases, spinosyn (Madduri
et al., 2001) and elloramycin (Ramos et al., 2008), a
rhamnose biosynthesis gene cluster has been identified in
other chromosomal location and most probably they use
L-rhamnose synthesized by the cell for other cellular func-
tions or structures. The involvement of this rhamnose
gene cluster in elloramycin biosynthesis was demon-
strated by inactivation of the rhaB gene, encoding a 4,6-
dehydratase, thus generating a non-producer mutant that
accumulated the elloramycin aglycon 8-demethyl-
tetracenomycin C (Ramos et al., 2008). In addition, a
Streptomyces peucetius rhamnose biosynthesis gene
cluster has been recently found to be involved in
daunorubicin/doxorubicin biosynthesis providing TDP-4-
keto-6-deoxy-D-glucose as precursor for the biosynthesis
of daunosamine (Singh et al., 2010). Inactivation of genes
involved in the production of deoxysugars from daunoru-
bicin and mithramycin clusters has also led to identify
non-glycosylated compounds (Lombó et al., 1997; Otten
et al., 1997) and derivatives with different patterns of gly-
cosylation (Remsing et al., 2002).
In the case of enediyne C-1025, in addition to a
deoxyamino sugar, genes for the biosynthesis of two
further structural elements are present in the cluster.
These elements are the b-amino acid (S)-3-chloro-4,5-
dihydroxy-b-phenylalanine (derived from L-tyrosine) and
benzoxazolinate (derived from chorismate). The biosyn-
thesis of the b-amino acid moiety involves, in addition to
other enzymes, different NRPS free standing domains
such as an adenylation (SgcC1) and a peptidyl carrier
protein (SgcC2) (Liu et al., 2002; Van Lanen et al., 2005;
2008). The inactivation of sgcA or sgcC1 involved in early
steps in the biosynthesis of the deoxyamino or b-amino
acid moieties led to abolish production of the final com-
pound and no intermediates or derivatives were accumu-
lated (Liu and Shen, 2000; Liu et al., 2002). On the other
hand, inactivation of sgcC, encoding a phenol hydroxy-
lase catalysing a late step for the biosynthesis of the
b-amino acid moiety, led to a new C-1027 derivative (Liu
et al., 2002; Van Lanen et al., 2005). These results
suggest that C-1027 structural elements are required to
stabilize the enediyne polyketide core. The lack of any of
these structural elements, including the benzoxazolinate
moiety (as will be described in the next section), deter-
mine the complete absence of any enediyne derivative.
Tailoring modifications. The introduction of additional
chemical modifications into the structural core is performed
by tailoring enzymes whose genes are found within the
biosynthesis gene cluster. Group transferases such as
glycosyl-, methyl-, acyl-, prenyl-, carbamoyl- or amino-
transferases belong to this class. Attachment of sugars is
carried out by glycosyltransferases, which catalyses the
transfer of the sugar from a NDP-activated sugar donor to
an acceptor molecule. In most of the cases, attachment of
the sugars to the aglycone occurs through O-glycosidic
linkages, but C- and N-glycosidic bonds also takes place.
Methyltransferases generally use SAM as methyl donor to
methylate functional groups either at the compound core or
at other structural moieties. Acyltransferases are involved
in the attachment of either short (C2–C6) or medium
(C8–C12) acyl chains to both amine and alcohol moieties.
The acyl transfer process is often one of the latest biosyn-
thetic events representing a key step in generating the final
biologically active molecule and, in some cases, it is an
important event for self-protection of the producing organ-
ism. Prenyltransferases catalyse the transfer of prenyl
moieties derived from allylic isoprenyl diphosphates (PP)
such as dimethylallyl-PP (C5), geranyl-PP (C10) or
farnesyl-PP (C15). Carbamoyltransferases catalyse the
attachment of carbamoyl moieties, and aminotransferases
incorporate amino groups. On the other hand, enzymes
that normally participate in the biosynthesis of structural
cores such NRPS can occasionally act as group trans-
ferases. This is the case of SgcC5, a NRPS free standing
condensation domain, which incorporates b-amino acid
(S)-3-chloro-4,5-dihydroxy-b-phenylalanine to the C-1027
polyketide core (Liu et al., 2002).
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Other tailoring modifications introduce oxygen-
containing functionalities, such as hydroxy, epoxide, alde-
hyde and keto groups, or modify these moieties by
addition or removal of hydrogen atoms. These reactions,
catalysed by oxygenases, oxidases, peroxidases, reduc-
tases and dehydrogenases, can provide a base for addi-
tional modifications such as methyl- amino- or glycosyl-
transfer. In addition, the introduction of chloride and
bromide in secondary metabolites is frequently performed
by halogenating enzymes known as flavin-dependent
halogenases.
Tailoring modification genes have also been subjected
to inactivation for validating gene clusters. This approach
usually generates mutants that accumulate biosynthetic
intermediates or novel derivatives. This is the case of
inactivation of several group transferases such as glyco-
syltransferases, methyltransferases, acyltransferases,
carbamoyltransferases, aminotransferases or halogena-
ses involved in the biosynthesis of daunorubicin (Otten
et al., 1995a), mithramycin (Fernández et al., 1998;
Blanco et al., 2000; Nur-e-Alam et al., 2005), chromomy-
cin A3 (Menéndez et al., 2004b; 2006), borrelidin (Olano
et al., 2004b), mitomycin C (Grüschow et al., 2007; Sita-
chitta et al., 2007), C-1027 (Liu et al., 2002), geldanamy-
cin (Shin et al., 2008), salinosporamide A (Eustáquio
and Moore, 2008) and bleomycin (Galm et al., 2008).
However, the inactivation of acyltransferase sgcD6
involved in the attachment of benzoxazolinate moiety to
C-1027 polyketide core abolished the production of
either the final compound or any other related compound
(Liu et al., 2002). This, as was mentioned before, points
to C-1027 structural elements, deoxyamino sugar,
b-amino acid and benzoxazolinate, to have a role as sta-
bilizing units for the polyketide core integrity. Further-
more, several oxidoreductases have been subjected to
inactivation for validating biosynthesis clusters, leading
to novel compounds derived from mithramycin (Remsing
et al., 2003), chromomycin A3 (Menéndez et al., 2004a),
borrelidin (Olano et al., 2004b), salinosporamide
(McGlinchey et al., 2008) or geldanamycin (Shin et al.,
2008).
Regulatory genes
The expression of genes from biosynthesis clusters is
normally controlled by pathway-specific regulatory genes.
They can have either positive (activators) or negative
(repressors) effects on gene expression. The number of
putative pathway-specific regulatory genes in different
clusters range from one in bleomycin, rebeccamycin or
staurosporine pathways to five in the rapamycin or thio-
coraline pathways (Table 1). However, in some pathways
no regulatory genes have been identified, as it is the case
of the borrelidin or elloramycin gene clusters.
Approximately half of the pathway-specific activators
belong to three groups of transcriptional factors contain-
ing DNA binding helix–turn–helix (HTH) signatures:
SARP- (seven cases), LuxR- (six cases) and TetR-family
(six cases) regulators. The Streptomyces Antibiotic Regu-
latory Protein family (SARP) share sequence similarity
with several members of the OmpR family of DNA-binding
domains. In particular, regulatory elements of this family
are mainly present in aromatic polyketide gene clusters
such as those involved in the biosynthesis of daunorubicin
(Stutzman-Engwall et al., 1992), mithramycin (Lombó
et al., 1999), chromomycin A3 (Menéndez et al., 2004a)
and steffimycin (Gullón et al., 2006). OmpR- and LuxR-
like regulators generally act as activators and TetR-family
transcriptional regulators generally act as repressors
(Ramos et al., 2005), but there are examples of TetR-like
positive regulators such as AtrA from Streptomyces
griseus (Hirano et al., 2008). Only two clusters (bleomycin
and C-1027) do not contain any regulatory element of
these families (Liu et al., 2002; Shen et al., 2002), while
daunorubicin cluster contains one of each (Stutzman-
Engwall et al., 1992; Otten et al., 1995b). The regulation
of the daunorubicin/doxorubicin production has been
studied in detail. Transcriptional regulator DnrO (BirA/
TetR-like) binds specifically to the overlapping dnrN/dnrO
promoter region activating the expression of response
regulator DnrN that contains a LuxR-like HTH motif. Then,
DnrN activates the transcription of dnrI whose product
DnrI, a SARP regulator, activates the production of dauno-
rubicin biosynthesis and resistance genes (Madduri and
Hutchinson, 1995; Otten et al., 1995b; 2000; Furuya and
Hutchinson, 1996; Sheldon et al., 2002). In addition, DnrO
has been shown to repress its own expression, effect that
could be relieved by the presence of rhodomycin D, one of
the first glycosylated intermediates in the daunorubicin/
doxorubicin pathway, and enhanced by the final products
(Jiang and Hutchinson, 2006; Ajithkumar and Prasad,
2010; Srinivasan et al., 2010). In most cases, inactivation
of positive regulatory genes led to completely abolish the
biosynthesis of the drug, the exception being mtrY of
the mithramycin pathway: its inactivation considerably
decreased (but did not abolish) mithramycin biosynthesis
(Garcia-Bernardo et al., 2000). On the other hand, inacti-
vation of negative regulatory genes led to an increase in
the production of the respective secondary metabolite.
This has been shown for mitomycin C mmcW (Mao et al.,
1999a) and chromomycin A3 cmmRII (Menéndez et al.,
2007). Some of these regulatory elements, both activators
and repressors, might be specifically involved in the
control of secondary metabolite resistance/transport
systems since they are located next to these elements in
several clusters. This is probably the case of regulatory
elements mmcW, mtrY and cmmRII from mitomycin C
(Mao et al., 1999a), mithramycin (Garcia-Bernardo et al.,
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2000) and chromomycin A3 (Menéndez et al., 2007) gene
clusters respectively.
Resistance and transport genes
Most antitumour compounds produced by actinomycetes
interact with DNA. Therefore, producer microorganisms
have developed mechanisms to survive during the bio-
synthesis of the drug. These resistance mechanisms
could be divided into two groups: resistance systems and
transport systems dedicated to self-defence and/or extru-
sion of the final compound or intermediates. Most clusters
(except those of salinosporamide A and staurosporine)
contain elements of both groups, and only in the case of
borrelidin cluster there is not transport system present.
The most extended resistance mechanism is a
UvrA-like protein found in daunorubicin/doxorubicin
(Lomovskaya et al., 1996), mithramycin (Fernández et al.,
1996; Garcia-Bernardo et al., 2000), C-1027 (Liu et al.,
2002), chromomycin A3 (Menéndez et al., 2004a; 2007)
and thiocoraline (Lombó et al., 2006) gene clusters. The
UvrA protein is an E. coli UvrABC complex homologue
involved in excision repair of UV-induced DNA lesions
(Truglio et al., 2006). This system has been shown to
repair DNA damaged by the free oxygen radicals pro-
duced from the interaction of anthracyclines to DNA. The
UvrA-like encoding genes have been inactivated in differ-
ent gene clusters showing various effects. In the dauno-
rubicin gene cluster the inactivation of drrC could only be
obtained in a non-producing mutant (Lomovskaya et al.,
1996). Furthermore, the expression of drrC is induced by
daunorubicin, and DrrC has been shown to bind DNA in
the presence of ATP and daunorubicin (Furuya and
Hutchinson, 1998). The inactivation of mtrX has no appar-
ent effect on mithramycin resistance but the expression of
this gene into heterologous host S. albus conferred
certain level of resistance to mithramycin (Garcia-
Bernardo et al., 2000). The inactivation of cmrX led to a
chromomycin A3 sensitive strain that, in addition, showed
a decreased production of the compound (Menéndez
et al., 2007). Moreover, this gene is required to confer a
high level of chormomycin A3 resistance in heterologous
hosts. Oxidases have also been reported as resistance
mechanisms to mitomycin C and anthracyclines. McrA
was shown to be able of re-oxidizing activated mitomycin
C before it can initiate the event leading to DNA cross-
linking (August et al., 1994; Johnson et al., 1997). Two
McrA homologues have been identified in the mitomycin
gene cluster: MitR and MmcM. The inactivation of mitR
and mmcM resulted in reduced mitomycin C production in
the mitR mutant strain while mmcM mutant displayed a
normal production level (Mao et al., 1999a). By analogy to
McrA, DrrD has been proposed to exert a re-oxidizing
activity to counteract the effects of the reduced antitumour
drugs daunorubicin and doxorubicin in S. peucetius
(Hutchinson, 1997). Furthermore, the bleomycin resis-
tance mechanism involves the inactivation of the drug
by an N-acetyltransferase (BlmB) (Sugiyama et al.,
1994a,b). On the other hand, the expression of borO,
encoding a borrelidin-resistant threonyl-tRNA synthetase,
into S. albus was shown to confer resistance to the drug
(Olano et al., 2004a).
Regarding the transport/resistance systems, these can
be grouped in two different classes. The first corresponds
to membrane proteins that mediate the extrusion of sec-
ondary metabolites in a coupled exchange with protons or
sodium ions. The second are ABC (ATP Binging Cas-
sette) transporter systems that couple the transport of the
antibiotic through the cell membrane to ATP hydrolysis.
The most widely distributed transport systems among the
clusters covered in this review are ABC transporters,
which have been found as the unique transporters in
daunorubicin/doxorubicin (Guilfoile and Hutchinson,
1991), rapamycin (Schwecke et al., 1995), mithramycin
(Fernández et al., 1996), chromomycin A3 (Menéndez
et al., 2004a), thiocoraline (Lombó et al., 2006) and acti-
nomycin D (Keller et al., 2010) biosynthesis gene clus-
ters. In the C-1027 cluster there are genes encoding a
Na+/H+ efflux pump and a membrane protein in addition to
the ATP-binding protein of an ABC transporter system (Liu
et al., 2002). In some cases the effect of these systems on
the resistance/transport of several compounds has been
investigated. The daunorubicin ABC transporter com-
posed by the DrrAATP-binding protein and the DrrB mem-
brane protein has been shown to confer resistance to
daunorubicin/doxorubicin when expressed in S. lividans
(Guilfoile and Hutchinson, 1991). On the other hand, dis-
ruption of the drrAB genes in S. peucetius resulted in a
mutant strain highly sensitive to daunorubicin and with
10-fold decrease in drug production (Srinivasan et al.,
2010). On the contrary, inactivation of mtrA, encoding the
ATP-binding component of mithramycin ABC transporter,
is lethal to Streptomyces argillaceus and could be only
achieved in a non-producing mutant. The expression of
mtrAB into S. albus conferred high level of resistance to
mithramycin (Fernández et al., 1996). In the case of chro-
momycin A3 ABC transporter, expression of cmrAB in
S. albus conferred only low level of chromomycin A3
resistance, but it confers a high level of resistance to
4A,4E-O-dideacetyl-chromomycin A3, a biosynthetic inter-
mediate of chromomycin A3. To achieve a chromomycin A3
high level of resistance in S. albus it was necessary to
coexpress the ABC transporter cmrAB together with the
UvrA-like encoding gene cmrX. These results pointed to
the participation of the ABC transporter CmrAB in the
chromomycin A3 biosynthesis process by extrusion of an
intermediate that might be then acetylated (final tailoring
modification) by the membrane-bound CmmA acetyltrans-
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ferase, and thus converted into the fully biologically active
chromomycin A3 (Menéndez et al., 2007).
In some cases, there are drug-binding proteins that
confer resistance to the compound by drug sequestering
or by participating in the transport process as ligand-
binding proteins. Genes encoding these drug-binding pro-
teins have been found in actinomycin D (Keller et al.,
2010), bleomycin (Sugiyama et al., 1994a; Shen et al.,
2002) and mitomycin C (Sheldon et al., 1997; 1999; Mao
et al., 1999a) gene clusters. BlmA is a bleomycin-binding
protein that confers resistance in E. coli by drug seques-
tering. In the case of mitomycin C Mrd is a resistance
protein that binds the drug conferring 30-fold increase
resistance when expressed into E. coli (Sheldon et al.,
1997; 1999). On the other hand, the mitomycin C trans-
locase Mct confers fivefold increase in resistance to mito-
mycin C in E. coli, while disruption of mct in Streptomyces
lavendulae resulted in a strain more sensitive to the drug.
Coexpression of mct and mrd in E. coli resulted in a
150-fold increase in resistance (Sheldon et al., 1999).
Other genes
To this group belong genes to which no specifc function
has been ascribed. This is the case of several genes from
the mitomycin C biosynthesis cluster (mitI, mmcA, mmcB
and mmcP). Its inactivation led to non-producer mutants
thus confirming their involvement in the biosynthesis of
mitomycin C (Mao et al., 1999a). Another example is
cagA found in C-1027 biosynthesis cluster (Liu et al.,
2002). C-1027 is a chromoprotein antibiotic composed of
a chromophore (Fig. 2) and an apoprotein encoded by
cagA (Liu and Shen, 2000). CagA is required for the
antibiotic activity of C-1027 due to the extreme lability of
the chromophore. However, inactivation of cagA has no
effect on the biosynthesis of the chromophore itself (Cui
et al., 2009).
Biotechnology processes using combinatorial
biosynthesis and metabolic engineering
Once a biosynthesis gene cluster has been isolated and
characterized, the available genetic information can be
used for the generation of novel derivatives or to improve
the production of both the native natural product and the
novel compounds generated (Fig. 3).
Generation of novel derivatives
The non-producer mutant strains generated by inactivat-
ing genes involved in the generation of starter units can
be used for precursor-directed biosynthesis of novel com-
pounds. This approach, known as mutational biosynthesis
or mutasynthesis, couples the utilization of chemical syn-
thesis with molecular biology (Kennedy, 2008). Several
non-natural compounds derived from different metabo-
lites such as rapamycin, borrelidin or salinosporamide
have been generated following this method (Fig. 5).
BC210 is a mutasynthetic derivative of rapamycin gener-
ated by feeding cyclohexane carboxylic acid to Strepto-
myces hygrocopicus mutant MG2-10. This compound
was found to be a better inhibitor of mTOR kinase activity
and to show anticancer activity both in vivo and in vitro
(Gregory et al., 2005). In addition, BC210 is not a
substrate of the multidrug resistance efflux pump
P-glycoprotein, has good oral bioavailability and has a
highly effective penetration of the blood–brain barrier,
which makes this compound a potential therapeutic drug
for the treatment of brain tumours (Zhang and Wilkinson,
2007). Six borrelidin derivatives were generated by muta-
synthesis using different dicarboxylic acids as starter units
(Moss et al., 2006). One of these derivatives, containing a
carboxyl-cyclobutane instead of a carboxyl-cyclopentane
moiety, was found to be 15-fold less cytotoxic than borre-
lidin but sixfold more antiangiogenic (Wilkinson et al.,
2006). Mutasynthesis has been used, in addition, to gen-
erate fluorosalinosporamide, a salinosporamide A ana-
logue produced by a Sa. tropica chlorinase salL mutant
that was supplemented with synthetic 5′-fluoro-5′-
deoxyadenosine. This compound is the most potent sali-
noporamide analogue showing high proteasome binding
properties in which the fluoro group significantly extends
its residence time on the proteasome (Eustáquio and
Moore, 2008).
Genetic manipulation of genes encoding condensing
enzymes has been a successful approach to generate
novel compounds with modifications in the structural core
from different natural products. As an example, acyltrans-
ferase substitution in geldanamycin PKS module 7
(GdmA3) by the rapamycin equivalent from module 2 led
to the production of several novel geldanamycin deriva-
tives. In particular, compound KOSN1559 (Fig. 5) showed
fourfold higher binding affinity towards Hsp90, a chaper-
one overproduced in several types of human cancers and
new target for cancer therapy (Patel et al., 2004). Occa-
sionally, modifications in the structural core can be
obtained by targeting genes involved in tailoring modifica-
tion. This is the case of insertional inactivation of mithra-
mycin mtmW, encoding a ketoreductase involved in side-
chain modification, which led to the production of several
new mithramycin derivatives (Remsing et al., 2003).
Among them, mithramycin SK (Fig. 5) showed an antitu-
mour activity ninefold higher than that of mithramycin
(Remsing et al., 2003), being especially effective against
colon carcinoma cells (Bataller et al., 2008; 2010).
Targeting genes involved in the generation of structural
elements attached to the core structure, including those
tailoring modification, is the most productive approach to
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generate novel derivatives. Examples are the production
of 22-dehydroxy-C-1027 and 3-morpholino-propylamine-
decarbamoyl-bleomycin (Fig. 6). The first one was gener-
ated by inactivating Streptomyces globisporus FAD-
dependent monooxygenase sgcC (Liu et al., 2002). The
second compound was produced by inactivating Strepto-
myces verticillus carbamoyltransferase blmD (Galm et al.,
2008). In addition, the expression of different gene com-
binations in a heterologous host can bypass the eventu-
ality of working with actinomycetes refractory to genetic
manipulation. This was the method used to obtain several
oviedomycin derivatives in S. albus by combining type II
PKS and cyclase genes together with those of three FAD-
dependent oxygenase genes from its own cluster. Three
of these derivatives: prejadomycin-2-carboxylate, preja-
domycin and 4a-12b-dehydro-UWM6 (Fig. 6), showed
significant improved antitumour activity (Lombó et al.,
2009).
The combination of targeting gene disruption and
expression of genes or combinations of genes has been
widely used to modify the glycosylation pattern of different
antitumour compounds (Figs 6 and 7). The important
Fig. 5. A. Structures of novel antitumour derivatives generated by mutasynthesis or modification of the structural core.
B. Altered features and their comparison with the unmodified compound.
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antitumour drug 4′-epidoxorubicin (epirubicin), tradition-
ally obtained semisynthetically, along with its precursor
4′-epidaunorubicin, was generated using a genetically
engineered S. peucetius strain defective in the daun-
osamine biosynthesis gene dnmV. This strain was used to
express the avermectin biosynthetic gene avrE from
Streptomyces avermitilis or the erythromycin biosynthetic
gene eryBIV from Saccharopolyspora erythraea, which
led to 4′-epianthracyclines (Madduri et al., 1998) (Fig. 6).
A number of anthracyclines with modification in the glyco-
sylation pattern have been obtained by expressing the
steffimycin gene cluster in S. albus together with plasmids
directing the biosynthesis of different deoxysugars. Three
of these compounds showed higher antitumour activity
than the parental natural product. In particular,
D-digitoxosyl-8-demethoxy-10-deoxysteffimycin (Fig. 7)
was found to be 24-fold more active than steffimycin when
tested against different human tumour cell lines (Olano
et al., 2008b). Analogues with improved activity of other
aromatic compounds such as mithramycin and elloramy-
cin have been also obtained by modification of the sugar
moieties. The expression of genes involved in the biosyn-
thesis of different deoxysugars in S. argillaceus led to 11
new mithramycin derivatives with altered glycosylation
patterns (Baig et al., 2008; Pérez et al., 2008). Two
of these, demycarosyl-3D-b-D-digitoxosyl-mithramycin
and deoliosyl-3C-b-D-mycarosyl-mithramycin, showed
improved activity against an oestrogen receptor-positive
human breast cancer cell line. In addition, demycarosyl-
3D-b-D-digitoxosyl-mithramycin was highly active against
an oestrogen receptor-negative human breast cancer cell
line that is not strongly inhibited by mithramycin (Baig
et al., 2008). On the other hand, coexpression of ellora-
mycin gene cluster in S. albus with plasmids directing the
biosynthesis of different deoxysugars has led to the iso-
lation of new elloramycin (R1=CH3) and 8-demethyl-
tetracenomycin C (R1=H) derivatives (Fig. 7) with different
sugar moieties (Fischer et al., 2002; Rodríguez et al.,
2002; Lombó et al., 2004b; Pérez et al., 2005; 2006).
From these compounds, L-mycarosyl-elloramycin showed
improved activity against three cancer cell lines (Lombó
et al., 2004b). The modification of glycosylation patterns
Fig. 6. Structures of novel antitumour derivatives generated by tailoring modification showing the genes inactivated (crossed) or expressed for
the generation of the novel compound.
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has not only been applied to polyketide natural products.
Several indolocarbazole derivatives were generated by
using this approach (Salas et al., 2005). Rebeccamycin, a
DNA topoisomerase I inhibitor, and staurosporine, a pro-
miscuous kinase inhibitor, contain a sugar moiety (Fig. 2)
attached through a single N-glycosidic bond (rebeccamy-
cin) or by two N-glycosidic bonds (staurosporine). The
coexpression of rebeccamycin and staurosporine biosyn-
thesis genes together with plasmids directing the biosyn-
thesis of deoxysugars in S. albus has allowed the
generation of novel derivatives from both compounds
(Fig. 7). Some of these analogues were found highly
active against specific kinases. L-olivosyl-arcyriaflavin A is
a potent inhibitor of Ikkb, kinase that prevents activation of
the NF-kB pathway and thus has potential application
on inflammation and cancer. On the other hand,
L-digitoxosyl-k252c is a subnanomolar JAK2 inhibitor,
kinase with potential application in myeloproliferative dis-
orders (Sánchez et al., 2009).
Improving production yields
Current methods to increase the productivity of industrial
microorganisms are classical random mutagenesis and
optimization of large-scale industrial fermentations. Meta-
bolic engineering can help, in addition, to improve the
production of bioactive metabolites (Fig. 3). Overproduc-
tion of a particular compound can be achieved by engi-
neering different aspects of cellular metabolism at the
level of primary metabolism such as precursor supply
or ribosome engineering. The production of bioactive
metabolites can also be improved by engineering genes
Fig. 7. Structures of novel antitumour derivatives with an altered glycosylation pattern by using plasmids directing the biosynthesis of different
deoxysugars.
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from their specific biosynthesis clusters: pathway-specific
regulators, structural and self-resistance genes. In addi-
tion, the expression of heterologous genes or the expres-
sion of the gene cluster in a heterologous host can be
used to enhance production yields.
At the level of primary metabolism, it has been
observed that overexpression of SAM synthetase results
in higher secondary metabolite yields. The characteriza-
tion of two S. peucetius SAM synthetase genes, metK1-sp
and metK2-sp, and their independent overexpression in
the same organism resulted in 2.1- and 1.4-fold increase
of doxorubicin production (Oh et al., 2010). Ribosome
engineering has been used as a rational approach to
enhance antibiotic production in different Streptomyces
spp. by selecting mutants resistant to several antibiotics.
In particular, ribosomes containing a mutation in riboso-
mal protein S12 gene, rpsL, which confers resistance to
streptomycin, led to high increases in secondary metabo-
lite production due to a high level of protein synthesis and
ppGpp accumulation (Wang et al., 2008). Actinomycin D
production in Streptomyces antibioticus has been
enhanced 5.2-fold by this method (Hosoya et al., 1998).
On the other hand, transport/resistance systems encoded
in the biosynthesis gene cluster have been observed to be
involved not only in self-protection but also in the export of
biologically active intermediates (Menéndez et al., 2007).
The production of doxorubicin by S. peucetius has been
enhanced by overexpressing the resistance genes drrA,
drrB and drrC in different combinations. The expression of
drrAB led to a 2.2-fold increase in doxorubicin yields while
the drrC led to a 5.1-fold increase. Surprisingly, only a
2.4-fold increase was obtained by expressing the three
genes together (Malla et al., 2010a). Consequently,
increasing self-resistance levels in producing organisms
can be also used as an approach for increasing produc-
tion yields.
Engineering pathway-specific regulators is a useful
method to bypass the imposed constrains to the expres-
sion of biosynthetic and transport/regulatory genes thus
deregulating the production of secondary metabolites.
Overexpression of pathway-specific activators under the
control of constitutive promoters and using multicopy
plasmids has been used to improve the production of
mithramycin (Lombó et al., 1999; Garcia-Bernardo et al.,
2000), daunorubicin (Stutzman-Engwall et al., 1992;
Otten et al., 1995b), doxorubicin (Parajuli et al., 2005;
Malla et al., 2010b), rapamycin (Kuscer et al., 2007) and
C-1025 (Wang et al., 2009). Furthermore, inactivation of
pathway-specific repressors can also lead to overproduc-
tion of secondary metabolites. This is the case of mitomy-
cin C (Mao et al., 1999a) and chromomycin A3 (Menéndez
et al., 2007) that were overproduced when pathway-
specific transcriptional repressors mmcW and cmmRII
were inactivated in their respective producer strains.
Biosynthesis structural genes can also be used to
improve secondary metabolite production. Overexpres-
sion of sgcA1, encoding a NDP-glucose synthase,
resulted in a twofold improvement for enediyne C-1027
production, and up to fourfold if cagA coding for C-1027
apoprotein was coexpressed (Murrell et al., 2004). On the
other hand, the expression of cagA alone, either as an
extra copy under a constitutive promoter or as multiple
copies of the gene under its native promoter, also resulted
in a significant increase in enediyne production (Cui et al.,
2009). The production of doxorubicin has also been
improved by expressing genes involved in the biosynthe-
sis and attachment of deoxyamino sugar daunosamine.
By expressing the daunorubicin glycosyltransferase
genes dnrS/dnrQ together with glucose-1-phosphate
thymidylyltransferase desIII and TDP-D-glucose-4,6-
dehydratase desIV from S. venezuelae involved in the
formation of the intermediate TDP-4-keto-6-deoxy-D-
glucose a 5.6-fold increase in doxorubicin yield
was obtained (Malla et al., 2009). The utilization of
heterologous genes has also allowed improving 4′-
epidaunorubicin yields in Streptomyces coeruleorubidus.
In this case, by increasing threefold the aveBIV (formerly
avrE) copy number, 4′-epidaunorubicin yields increased in
the same proportion (Shao et al., 2010). The expression
of heterologous genes in mutant strains can also be used
to bypass the utilization of mutasynthesis approaches for
the generation of certain derivatives. The production of
fluorosalinosporamide, generated by mutasynthesis, has
been induced in Sa. tropica by replacing the chlorinase
gene salL with the fluorinase gene flA from Streptomyces
cattleya (Eustáquio et al., 2010).
Another approach for improving metabolite production
is to remove genes involved in the generation of undes-
ired compounds thus enhancing the yields of the desired
one. Following this philosophy, inactivation of S. peucetius
dnrX and dnrH improved 3- and 8.5-fold the biosynthesis
of doxorubicin and daunorubicin respectively (Scotti and
Hutchinson, 1996; Lomovskaya et al., 1998). These
genes are involved in the transformation of daunorubicin
and doxorubicin into their polyglycosylated forms known
as baumycins. In addition, disruption of dnrU, involved
in the transformation of daunorubicin into 13-
dihydrodaunorubicin, has a similar effect on doxorubicin
production since the production of an undesired com-
pound is abolished (Lomovskaya et al., 1999). The com-
bination of these beneficial gene disruptions further
improved doxorubicin yield, up to sevenfold in the dnrU/
dnrX double mutant and to 26-fold in the dnrU/dnrX/dnrH
triple mutant. Furthermore, an additional 1.3- to 2.8-fold
increase was obtained by overexpressing in the double or
triple mutants mentioned above dnrV and doxA genes
involved in late steps during doxorubicin biosynthesis
(Lomovskaya et al., 1999). Using the same approach,
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overexpression of dnmT, involved in the biosynthesis of
daunorubicin deoxysugar L-daunosamine, in the dnrH
mutant led to improve daunorubicin production (Scotti and
Hutchinson, 1996). The production of 4′-epidaunorubicin
in S. peucetius dnmV::avrE was enhanced also by inac-
tivating dnrH and overexpressing dnmT (Madduri et al.,
1998).
Occasionally, it is important to narrow the substrate
flexibility of an enzyme to make it more efficient for the
generation of certain derivatives. This objective can be
accomplished by site-directed mutagenesis targeting spe-
cific residues in the substrate binding region. Using this
approach, elloramycin glycosyltransferase ElmGT that
possesses remarkable donor substrate flexibility has
been engineered to enhance the production of different
8-demethyl-tetracenomycin C derivatives. As mentioned
above ElmGT has been shown to transfer at least 11
different sugars, including both L- and D-isomeric forms, to
its aglycon. Site-directed mutagenesis in certain residues
located in the a/b/a motif within the ElmGT nucleoside
diphosphate-sugar binding region has led to obtain
several versions of the enzyme with improved ability to
transfer particular deoxysugars: D-boivinose 1.5-fold,
L-rhamnose twofold and L-olivose up to sixfold (Ramos
et al., 2009).
Finally, in some cases production titres can be
enhanced by expressing the biosynthesis gene cluster in
a heterologous host. This was the case of the indolocar-
bazole rebeccamycin produced by Lechevaleria aero-
colonigenes. The expression of the cluster in S. albus led
to production levels several folds higher than those of the
original strain (Sánchez et al., 2002).
Future perspectives
A great effort has been made in the last decades for the
discovery of new natural products, antitumour drugs
included. However, many of the novel compounds identi-
fied usually present some undesired biological and chemi-
cal properties, i.e. unspecific cytotoxicity, side-effects, no
effect on resistant strains or lack of solubility for oral or
parenteral administration, which represent a step back in
the expectations for their commercial use. The develop-
ment of recombinant DNA technology during the second
part of the last century has set up the foundations for
unravelling the information encoded in microbial genomes
and to access the information regarding the biosynthesis
of natural products. All the efforts executed for the isola-
tion, characterization and manipulation of biosynthesis
gene clusters have crystallized in the generation of a large
number of analogues of bioactive compounds. Some of
these compounds show improved biological properties,
which make them lead compounds for their application in
clinic. In addition, these gene clusters contain elements
that can be used to increase the production of both natural
and engineered products. Keeping on with combinatorial
biosynthesis approaches will provide increasing numbers
of safer and more specific compounds that might enhance
the arsenal of antitumour drugs available for chemo-
therapy.
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